Chief Scientific Officer of Synergy Pharmaceuticals to Give Keynote Presentation at the 17th Annual TIDES Summit

NEW YORK--(BUSINESS WIRE)--

Synergy Pharmaceuticals Inc. SGYP, today announced its Chief Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a keynote presentation at the 17^th Annual TIDES Summit being held May 3-6, 2015 in San Diego, CA.

The session titled, "Plecanatide and SP-333, Analogues of Uroguanylin, as Innovative Oral Drugs for Treatment of Gastrointestinal Disorders and Diseases", will be on Monday, May 4^th at 11:20am (PDT) at the Town and Country Resort.

The presentation will discuss the key role of uroguanylin as the naturally occurring human GI peptide and the unique pharmacological profiles of plecanatide and SP-333 for treating a variety of GI conditions.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the research and development of novel therapies to treat GI diseases and disorders. Synergy's proprietary platform technology is based on the naturally occurring human GI peptide, uroguanylin, a key regulator of normal GI physiology. The company's first uroguanylin analogue, plecanatide, is currently in pivotal phase 3 clinical trials for chronic idiopathic constipation and irritable bowel syndrome with constipation. Synergy's next-generation uroguanylin analogue, SP-333, has successfully completed a phase 2 study for opioid-induced constipation and is currently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.